Agency Forms Undergoing Paperwork Reduction Act Review, 48144-48145 [2021-18539]
Download as PDF
<![CDATA[
48144
Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–1102]
lotter on DSK11XQN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Tuberculosis
Data from Panel Physicians to the Office
of Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on May 26,
2021 to obtain comments from the
public and affected agencies. CDC
received one non-substantive comment
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
VerDate Sep<11>2014
17:52 Aug 26, 2021
Jkt 253001
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Tuberculosis Data from Panel
Physicians (OMB Control No. 0920–
1102, Exp. 9/30/2021)—Revision—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention’s (CDC), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Division of Global
Migration and Quarantine (DGMQ),
Immigrant, Refugee, and Migrant Health
Branch (IRMH), requests approval for a
Revision to an approved information
collection. The respondents are U.S.
panel physicians. Panel physicians are
medically trained, licensed, and
experienced medical doctors practicing
overseas who are appointed by the local
U.S. Embassy or Consulate General to
perform medical examinations for
prospective immigrants to the United
States. More than 760 panel physicians
perform overseas pre-departure medical
examinations at 336 panel sites, in
accordance with requirements, referred
to as Technical Instructions, provided
by the Centers for Disease Control and
Prevention’s Division of Global
Migration and Quarantine, Quality
Assessment Program (QAP). The QAP
program is housed in the Immigrant,
Refugee, and Migrant Health Branch
(IRMH). The role of QAP is to assist and
guide panel physicians in the
implementation of the Technical
Instructions; evaluate the quality of the
overseas medical examination for U.S.bound immigrants and refugees; assess
potential panel physician sites; and
provide recommendations to the U.S.
Department of State in matters of
immigrant medical screening.
To achieve DGMQ’s mission, IRMH
works with domestic and international
programs to improve the health of U.S.bound immigrants and refugees to
protect the U.S. public by preventing
the importation of infectious disease.
These goals are accomplished through
IRMH’s oversight of medical exams
required for all U.S.-bound immigrants
and refugees who seek permanent
residence in the U.S. IRMH is
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
responsible for assisting and training the
international panel physicians with the
implementation of medical exam
Technical Instructions. CDC’s Technical
Instructions are detailed requirements
and national policies regarding the
medical screening and treatment of all
U.S.-bound immigrants and refugees.
Screening for tuberculosis (TB) is a
particularly important component of the
immigration medical exam and allows
panel physicians to diagnose active TB
disease prior to arrival in the United
States. As part of the Technical
Instructions requirements, panel
physicians perform chest x-rays and
laboratory tests that aid in the
identification of tuberculosis infection
(Class B1 applicants) and diagnosis of
active tuberculosis disease (Class A,
inadmissible applicants). CDC uses
these classifications to report new
immigrant and refugee arrivals with a
higher risk of developing TB disease to
U.S. state and local health departments
for further follow-up. Some information
that panel physicians collect as part of
the medical exam is not reported on the
standard Department of State forms (DSforms), thereby preventing CDC from
evaluating TB trends in globally mobile
populations and monitoring program
effectiveness.
In 2007, CDC revised the Tuberculosis
Technical Instructions to include
several new requirements for
Mycobacteria tuberculosis (MTB) testing
and treatment. Important changes
included the requirements for: (1)
Sputum cultures in addition to sputum
smears; (2) tuberculin skin tests or
interferon gamma release assays
(beginning in 2009) for certain children
aged 2–14 years examined in countries
where the World Health Organization
estimated TB incidence is ≥20 per
100,000 persons; (3) drug-susceptibility
testing of positive isolates; and (4)
treatment being delivered as directly
observed therapy (DOT) throughout the
entire course.
Since implementation of these new
Culture and Directly Observed Therapy
TB Technical Instructions (CDOT TB
TI), overseas TB case detection has
increased by an estimated 60% and
allowed U.S. public health programs to
save millions of dollars annually.
Overseas TB screening data (referred to
by DGMQ as ‘TB Indicator data’) is
critical to support the continued
analysis of these trends and the
monitoring of TB control efforts in the
U.S.
CDC requests this data collection
approval for three years. This Revision
includes a decrease in respondents from
336 to 333, and a decrease in the
requested number of burden hours from
E:\FR\FM\27AUN1.SGM
27AUN1
48145
Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices
1,008 hours to 999. There is no cost to
respondents other than their time to
participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
International Panel Physicans ........................
TB Indicators REDCap web form ..................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–18539 Filed 8–26–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–1182]
Agency Forms Undergoing Paperwork
Reduction Act Review
lotter on DSK11XQN23PROD with NOTICES1
Number of
respondents
Type of respondents
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Formative
Research to Develop HIV Social
Marketing Campaigns for Healthcare
Providers’’ to the Office of Management
and budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on March 8,
2021 to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
VerDate Sep<11>2014
17:52 Aug 26, 2021
Jkt 253001
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Formative Research to Develop HIV
Social Marketing Campaigns for
Healthcare Providers (OMB Control No.
0920–1182)—Reinstatement without
Change—National Center for HIV/AIDS,
Viral Hepatitis, STD and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
To address the HIV epidemic in the
U.S., the Department of Health and
Human Services launched Ending the
HIV Epidemic: A Plan for America,
which is a cross-agency initiative
aiming to reduce new HIV infections in
the U.S. by 90% by 2030. CDC’s Let’s
Stop HIV Together campaign (formerly
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
333
Number of
responses per
respondent
1
Average
burden per
response
(in hours)
3
known as Act Against AIDS) is part of
the national Ending the HIV Epidemic
initiative and includes resources aimed
at reducing HIV stigma and promoting
testing, prevention, and treatment across
the HIV care continuum.
Within this context, CDC’s Division of
HIV/AIDS Prevention (DHAP) has, and
will continue implementing various
communication initiatives to increase
healthcare providers’ awareness of HIV
testing-, prevention- and treatmentrelated topics; reduce new HIV
infections among disproportionately
impacted populations; and improve
health outcomes for people living with
HIV/AIDS in the US and its territories.
Specifically, the initiatives target
healthcare providers, including primary
care, and relevant specialties such as
HIV medicine and infectious disease,
physicians, physician assistants, and
nurses.
The rounds of data collection include
exploratory, message testing, concept
testing, and materials testing.
Information collected by DHAP will be
used to assess healthcare providers’
informational needs about topics related
to HIV testing, prevention, and
treatment; pre-test campaign-related
messages, concepts, and materials; and
evaluate the extent to which the
communication initiatives are reaching
the target audiences and providing them
with trusted HIV-related information.
Data collections will include in-depth
interviews and brief surveys. The data
gathered under this request will be
summarized in reports prepared for CDC
by its contractor, such as quarterly and
annual reports and topline reports that
summarize results from each data
collection. It is possible that data from
this project will be published in peerreviewed manuscripts or presented at
conferences, and the manuscripts and
conference presentations may appear on
the internet.
The total estimated annualized
burden hours are 902. Participation of
respondents is voluntary, and there is
no cost to participants other than their
time.
E:\FR\FM\27AUN1.SGM
27AUN1
]]>Agencies
[Federal Register Volume 86, Number 164 (Friday, August 27, 2021)]
[Notices]
[Pages 48144-48145]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-18539]
[[Page 48144]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-21-1102]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Tuberculosis Data from Panel Physicians to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on May 26, 2021 to obtain comments
from the public and affected agencies. CDC received one non-substantive
comment related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Tuberculosis Data from Panel Physicians (OMB Control No. 0920-1102,
Exp. 9/30/2021)--Revision--National Center for Emerging and Zoonotic
Infectious Diseases (NCEZID), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention's (CDC), National
Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division
of Global Migration and Quarantine (DGMQ), Immigrant, Refugee, and
Migrant Health Branch (IRMH), requests approval for a Revision to an
approved information collection. The respondents are U.S. panel
physicians. Panel physicians are medically trained, licensed, and
experienced medical doctors practicing overseas who are appointed by
the local U.S. Embassy or Consulate General to perform medical
examinations for prospective immigrants to the United States. More than
760 panel physicians perform overseas pre-departure medical
examinations at 336 panel sites, in accordance with requirements,
referred to as Technical Instructions, provided by the Centers for
Disease Control and Prevention's Division of Global Migration and
Quarantine, Quality Assessment Program (QAP). The QAP program is housed
in the Immigrant, Refugee, and Migrant Health Branch (IRMH). The role
of QAP is to assist and guide panel physicians in the implementation of
the Technical Instructions; evaluate the quality of the overseas
medical examination for U.S.-bound immigrants and refugees; assess
potential panel physician sites; and provide recommendations to the
U.S. Department of State in matters of immigrant medical screening.
To achieve DGMQ's mission, IRMH works with domestic and
international programs to improve the health of U.S.-bound immigrants
and refugees to protect the U.S. public by preventing the importation
of infectious disease. These goals are accomplished through IRMH's
oversight of medical exams required for all U.S.-bound immigrants and
refugees who seek permanent residence in the U.S. IRMH is responsible
for assisting and training the international panel physicians with the
implementation of medical exam Technical Instructions. CDC's Technical
Instructions are detailed requirements and national policies regarding
the medical screening and treatment of all U.S.-bound immigrants and
refugees.
Screening for tuberculosis (TB) is a particularly important
component of the immigration medical exam and allows panel physicians
to diagnose active TB disease prior to arrival in the United States. As
part of the Technical Instructions requirements, panel physicians
perform chest x-rays and laboratory tests that aid in the
identification of tuberculosis infection (Class B1 applicants) and
diagnosis of active tuberculosis disease (Class A, inadmissible
applicants). CDC uses these classifications to report new immigrant and
refugee arrivals with a higher risk of developing TB disease to U.S.
state and local health departments for further follow-up. Some
information that panel physicians collect as part of the medical exam
is not reported on the standard Department of State forms (DS-forms),
thereby preventing CDC from evaluating TB trends in globally mobile
populations and monitoring program effectiveness.
In 2007, CDC revised the Tuberculosis Technical Instructions to
include several new requirements for Mycobacteria tuberculosis (MTB)
testing and treatment. Important changes included the requirements for:
(1) Sputum cultures in addition to sputum smears; (2) tuberculin skin
tests or interferon gamma release assays (beginning in 2009) for
certain children aged 2-14 years examined in countries where the World
Health Organization estimated TB incidence is >=20 per 100,000 persons;
(3) drug-susceptibility testing of positive isolates; and (4) treatment
being delivered as directly observed therapy (DOT) throughout the
entire course.
Since implementation of these new Culture and Directly Observed
Therapy TB Technical Instructions (CDOT TB TI), overseas TB case
detection has increased by an estimated 60% and allowed U.S. public
health programs to save millions of dollars annually. Overseas TB
screening data (referred to by DGMQ as `TB Indicator data') is critical
to support the continued analysis of these trends and the monitoring of
TB control efforts in the U.S.
CDC requests this data collection approval for three years. This
Revision includes a decrease in respondents from 336 to 333, and a
decrease in the requested number of burden hours from
[[Page 48145]]
1,008 hours to 999. There is no cost to respondents other than their
time to participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
International Panel Physicans......... TB Indicators REDCap web 333 1 3
form.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-18539 Filed 8-26-21; 8:45 am]
BILLING CODE 4163-18-P
